A follow-up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China

Chinese Medical Journal

Volumn 125, Issue 4, 2012, Pages 646-651

  Kang, Hui Cong ^a   Hu, Qi ^a   Liu, Xiao Yan ^a   Liu, Zhi Guang ^a   Zeng, Zheng ^a   Liu, Jian Lin ^a   Wang, Min ^a   Liang, Yan Ling ^a   Zhu, Sui Qiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Add on therapy; Efficacy; Monotherapy; New anti epileptic drug; Partial epilepsy; Safety

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; AMNESIA; ANHIDROSIS; ANOREXIA; ANTISOCIAL BEHAVIOR; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHARACTER DISORDER; CHILD; CHINA; COMPLEX PARTIAL SEIZURE; CONCENTRATION LOSS; CONTROLLED STUDY; DIPLOPIA; DISEASE DURATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EXCITATION; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HAIR LOSS; HEMATOLOGIC DISEASE; HUMAN; HYPOLEUKOCYTOSIS; HYPONATREMIA; IRRITABILITY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MONOTHERAPY; PARESTHESIA; PRESCHOOL CHILD; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SOMNOLENCE; SPEECH DISORDER; STUDY; TONIC CLONIC SEIZURE; TREMOR; URINARY TRACT DISEASE; WEIGHT REDUCTION;

ANTICONVULSANTS; CARBAMAZEPINE; CHINA; EPILEPSIES, PARTIAL; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; TREATMENT OUTCOME; TRIAZINES;

EID: 84863182773     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.04.016     Document Type: Article

References (27)

1. Ding D, Hong Z, Wang WZ, Wu JZ, de Boer HM, Prilipko L, et al. Assessing the disease burden due to epilepsy by disability adjusted life year in rural China. Epilepsia 2006; 47: 2032-2037.
2. Rau J, May TW, Pfäfflin M, Heubrock D, Petermann F. Education of children with epilepsy and their parents by the modular education program epilepsy for families (FAMOSES) - results of an evaluation study. Rehabilitation (Stuttg) 2006; 45: 27-39.
3. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-1260.
4. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-1273.
5. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005; 9: 1-157, iii-iv.
6. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120.
7. National Institute for Clinical Excellence. Newer drugs for epilepsy. London: NICE London; 2004. (Accessed 4 May 2004 at http://www.nice.org.uk/TA076guidance)
8. Vazquez B. Monotherapy in epilepsy: role of the newer antiepileptic drugs. Arch Neurol 2004; 61: 1361-1365.
9. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85-110.
10. Grosso S, Franzoni E, Iannetti P, Incorpora G, Cardinali C, Toldo I, et al. Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol 2005; 20: 893-897.
11. Kraiprab P, Chinvarun Y, Tantisira MH. Oxcarbazepine as add-on therapy in Thai epileptic patients with refractory partial seizures. J Med Assoc Thai 2005; 88 Suppl 3: S193-S201.
12. Chen SJ, Chang KP, Wong TT, Kwan SY, Hsu ML, Wang CC. Lamotrigine adjunctive therapy in children with refractory epilepsy: a medical center study. Acta Paediatr Taiwan 2006; 47: 123-126.
13. Beydoun A, Sachdeo RC, Kutluay E, McCague K, D'Souza J. Sustained efficacy and long-term safety of Oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia 2003; 44: 1160-1165.
14. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, et al. Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 2008; 17: 19-26.
15. Schmidt D, Arroyo S, Baulac M, Dam M, Dulac O, Friis ML, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001; 104: 167-170.
16. Steinhoff BJ, Hirsch E, Mutani R, Nakken KO. The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs. Acta Neurol Scand 2003; 107: 87-95.
17. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006; 15: 637-647.
18. Horga de la Parte JF, Horga A. Oxcarbazepine in the treatment of epilepsy. A review and update. Rev Neurol 2006; 42: 95-113.
19. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65: 1976-1978.
20. Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000; 54: 2245-2251.
21. Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 2000; 1: 396-405.
22. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 Suppl 4: 21-29.
23. Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs 2000; 2: 299-330.
24. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007; 48: 1360-1365.
25. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006; 114: 157-168.
26. Tatum WO 4th, French JA, Faught E, Morris GL 3rd, Liporace J, Kanner A, et al. PADS Investigators. Post-marketing antiepileptic drug survey. Postmarketing experience with topiramate and cognition. Epilepsia 2001; 42: 1134-1140.
27. Korian Topiramate Study Group. Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicentre open clinical trial. Seizure 2002; 11: 255-260.